RECODE THERAPEUTICS
Startup
RECODE THERAPEUTICS
Description
ReCode Therapeutics develops a selective organ targeting (SORT) lipid nanoparticle (LNP) platform designed for enabling precise delivery to target organs and cells beyond the liver. The SORT LNP platform is the foundation for ReCode’s pipeline of disease-modifying mRNA and gene correction therapeutics.
Resources
RECODE THERAPEUTICS
Address
1455 ADAMS DRIVE MENLO PARK, CALIFORNIA 94025 UNITED STATES
United States
United States
Contact
partnering@recodetx.com
Description
ReCode Therapeutics develops a selective organ targeting (SORT) lipid nanoparticle (LNP) platform designed for enabling precise delivery to target organs and cells beyond the liver. The SORT LNP platform is the foundation for ReCode’s pipeline of disease-modifying mRNA and gene correction therapeutics.
Resources
Matchmaking
Connect with RECODE THERAPEUTICS
This entity is yours?
Update informationPosition on the value chain
With the ultimate aim to create a European alliance for bioproduction in Europe, organisations have joined forces with COBIOE. Discover who are our associates.
Bio-resources and biobanking
- Cells, tissues and humanized xeno-organs
- Biosamples
- Viral, phage or bacterial specimen
Identification of biotherapies
- Target identification
- Target validation
- Screening
Drug design
- Drug assessment
- Drug engineering
- In vitro preclinical studies
Clinical validation
- Clinical trials
- In vivo preclinical validation
- Pre-industrial scale production
Production
- Upstream processes
- Downstream processes
- Quality control
Market access
- CE mark / market authorisation
- Payment / Reimbursement
- Care pathways